(Q43048589)

12 November 2017

title

The design of potent, non-peptidic inhibitors of hepatitis C protease (English)

1 reference

12 November 2017

author

David Michael Andrews

1

1 reference

12 November 2017

Helene M Chaignot

2

1 reference

12 November 2017

Barry A Coomber

3

1 reference

12 November 2017

Mike D Dowle

4

1 reference

12 November 2017

S Lucy Hind

5

1 reference

12 November 2017

Martin R Johnson

6

1 reference

12 November 2017

Paul S Jones

7

1 reference

12 November 2017

Gail Mills

8

1 reference

12 November 2017

Angela Patikis

9

1 reference

12 November 2017

Tony J Pateman

10

1 reference

12 November 2017

J Ed Robinson

11

1 reference

12 November 2017

Martin J Slater

12

1 reference

12 November 2017

Naimisha Trivedi

13

1 reference

12 November 2017

publication date

1 April 2003

1 reference

European Journal of Medicinal Chemistry

12 November 2017

published in

1 reference

12 November 2017

volume

38

1 reference

12 November 2017

issue

4

1 reference

12 November 2017

page(s)

339-343

1 reference

Relation of hepatitis C virus to hepatocellular carcinoma

12 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2803%2900050-3

7 January 2021

Epidemiology of hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2803%2900050-3

7 January 2021

Hepatitis C: the clinical spectrum of disease

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2803%2900050-3

7 January 2021

Hepatitis C virus NS3/4A protease

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2803%2900050-3

7 January 2021

Therapy of viral hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2803%2900050-3

7 January 2021

https://api.crossref.org/works/10.1016%2FS0223-5234%2803%2900050-3

1 reference

7 January 2021

Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2803%2900050-3

7 January 2021

Therapy of hepatitis C: alpha interferon and ribavirin

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2803%2900050-3

7 January 2021

Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2803%2900050-3

7 January 2021

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2803%2900050-3

7 January 2021

Molecular virology of hepatitis C virus

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2803%2900050-3

7 January 2021

The molecular virology of hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2803%2900050-3

7 January 2021

Mechanistic role of an NS4A peptide cofactor with the truncated NS3 protease of hepatitis C virus: elucidation of the NS4A stimulatory effect via kinetic analysis and inhibitor mapping

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2803%2900050-3

7 January 2021

Hepatitis C virus-encoded enzymatic activities and conserved RNA elements in the 3' nontranslated region are essential for virus replication in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2803%2900050-3

7 January 2021

Hepatitis C virus protease inhibitors: current progress and future challenges

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2803%2900050-3

7 January 2021

On the size of the active site in proteases. I. Papain

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2803%2900050-3

7 January 2021

Design and synthesis of ethyl pyrrolidine-5,5-trans-lactams as inhibitors of hepatitis C virus NS3/4A protease

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2803%2900050-3

7 January 2021

The discovery of a potent, intracellular, orally bioavailable, long duration inhibitor of human neutrophil elastase--GW311616A a development candidate

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2803%2900050-3

7 January 2021

Orally Active .beta.-Lactam Inhibitors of Human Leukocyte Elastase. 3. Stereospecific Synthesis and Structure-Activity Relationships for 3,3-Dialkylazetidin-2-ones

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2803%2900050-3

7 January 2021

Pyrrolidine-5,5-trans-lactams. 1. Synthesis and incorporation into inhibitors of hepatitis C virus NS3/4A protease

1 reference

https://api.crossref.org/works/10.1016%2FS0223-5234%2803%2900050-3

7 January 2021

10.1016/S0223-5234(03)00050-3

Identifiers

DOI

1 reference

12 November 2017

1 reference